225 related articles for article (PubMed ID: 33624577)
41. KRAS
Kyriakopoulos G; Katopodi V; Skeparnias I; Kaliatsi EG; Grafanaki K; Stathopoulos C
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672357
[TBL] [Abstract][Full Text] [Related]
42. The outcomes of an impaired powerhouse in KRAS mutant lung adenocarcinoma cells by Elesclomol.
Albayrak G; Korkmaz FD; Tozcu D; Dogan Turacli I
J Cell Biochem; 2019 Jun; 120(6):10564-10571. PubMed ID: 30628735
[TBL] [Abstract][Full Text] [Related]
43. Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer.
Ricciuti B; Brambilla M; Cortellini A; De Giglio A; Ficorella C; Sidoni A; Bellezza G; Crinò L; Ludovini V; Baglivo S; Metro G; Chiari R
Clin Transl Oncol; 2020 May; 22(5):708-716. PubMed ID: 31332704
[TBL] [Abstract][Full Text] [Related]
44. Performance evaluation of a fully closed real-time PCR platform for the detection of KRAS p.G12C mutations in liquid biopsy of patients with non-small cell lung cancer.
Gragnano G; Nacchio M; Sgariglia R; Conticelli F; Iaccarino A; De Luca C; Troncone G; Malapelle U
J Clin Pathol; 2022 May; 75(5):350-353. PubMed ID: 33649142
[TBL] [Abstract][Full Text] [Related]
45. Targeted sequencing and intracranial outcomes of patients with lung adenocarcinoma brain metastases treated with radiotherapy.
Press RH; Zhang C; Cassidy RJ; Ferris MJ; Zhong J; Steuer CE; Pillai RN; Owonikoko TK; Kahn S; Ramalingam SS; Patel PR; Curran WJ; Shu HG; Sica GL; Higgins KA
Cancer; 2018 Sep; 124(17):3586-3595. PubMed ID: 30120912
[TBL] [Abstract][Full Text] [Related]
46. KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor.
Serna-Blasco R; Sánchez-Herrero E; Sanz-Moreno S; Rodriguez-Festa A; García-Veros E; Casarrubios M; Sierra-Rodero B; Laza-Briviesca R; Cruz-Bermúdez A; Mielgo-Rubio X; Sánchez-Hernández A; Uribelarrea EA; Calvo V; Romero A; Provencio M
ESMO Open; 2021 Oct; 6(5):100279. PubMed ID: 34607284
[TBL] [Abstract][Full Text] [Related]
47. Adagrasib in Non-Small-Cell Lung Cancer Harboring a
Jänne PA; Riely GJ; Gadgeel SM; Heist RS; Ou SI; Pacheco JM; Johnson ML; Sabari JK; Leventakos K; Yau E; Bazhenova L; Negrao MV; Pennell NA; Zhang J; Anderes K; Der-Torossian H; Kheoh T; Velastegui K; Yan X; Christensen JG; Chao RC; Spira AI
N Engl J Med; 2022 Jul; 387(2):120-131. PubMed ID: 35658005
[TBL] [Abstract][Full Text] [Related]
48. Correlation between KRAS mutation subtypes and prognosis in Chinese advanced non-squamous non-small cell lung cancer patients.
Liu F; Wang F; He J; Zhou S; Luo M
Cancer Med; 2023 Jun; 12(12):13123-13134. PubMed ID: 37140194
[TBL] [Abstract][Full Text] [Related]
49. Prognostic value of KRAS G12C mutation in lung adenocarcinoma stratified by stages and radiological features.
Cao H; Ma Z; Li Y; Zhang Y; Chen H
J Thorac Cardiovasc Surg; 2023 Dec; 166(6):e479-e499. PubMed ID: 37142051
[TBL] [Abstract][Full Text] [Related]
50. Prognostic value and therapeutic implications of expanded molecular testing for resected early stage lung adenocarcinoma.
Kneuertz PJ; Carbone DP; D'Souza DM; Shilo K; Abdel-Rasoul M; Zhao W; Williams TM; Jones D; Merritt RE
Lung Cancer; 2020 May; 143():60-66. PubMed ID: 32208298
[TBL] [Abstract][Full Text] [Related]
51. Mutational profiles of primary pulmonary adenocarcinoma and paired brain metastases disclose the importance of KRAS mutations.
Vassella E; Kashani E; Zens P; Kündig A; Fung C; Scherz A; Herrmann E; Ermis E; Schmid RA; Berezowska S
Eur J Cancer; 2021 Dec; 159():227-236. PubMed ID: 34781171
[TBL] [Abstract][Full Text] [Related]
52. EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma.
Chalela R; González-García JG; Khilzi K; Curull V; Sánchez-Font A; Longarón R; Rodrigo-Calvo MT; Martín-Ontiyuelo C; Gea J; Bellosillo B
Pathol Oncol Res; 2021; 27():598292. PubMed ID: 34257550
[TBL] [Abstract][Full Text] [Related]
53. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
Fathi Z; Mousavi SAJ; Roudi R; Ghazi F
PLoS One; 2018; 13(7):e0200633. PubMed ID: 30048458
[TBL] [Abstract][Full Text] [Related]
54. Coexistence of two missense mutations in the KRAS gene in adenocarcinoma of the lung: a possible indicator of poor prognosis.
Spinelli M; Du Parcq P; Gupta N; Khorashad J; Viola P
Pathologica; 2022 Jun; 114(3):221-227. PubMed ID: 35775708
[TBL] [Abstract][Full Text] [Related]
55. Identification of
Thein KZ; Biter AB; Banks KC; Duda AW; Saam J; Roszik J; Janku F; Skoulidis F; Heymach JV; Kopetz S; Meric-Bernstam F; Hong DS
JCO Precis Oncol; 2022 Jul; 6():e2100547. PubMed ID: 35862868
[TBL] [Abstract][Full Text] [Related]
56. Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With
Negrao MV; Spira AI; Heist RS; Jänne PA; Pacheco JM; Weiss J; Gadgeel SM; Velastegui K; Yang W; Der-Torossian H; Christensen JG; Sabari JK
J Clin Oncol; 2023 Oct; 41(28):4472-4477. PubMed ID: 37327468
[No Abstract] [Full Text] [Related]
57. Flavopiridol's effects on metastasis in KRAS mutant lung adenocarcinoma cells.
Dogan Turacli I; Demirtas Korkmaz F; Candar T; Ekmekci A
J Cell Biochem; 2019 Apr; 120(4):5628-5635. PubMed ID: 30317654
[TBL] [Abstract][Full Text] [Related]
58. Loss of wild type KRAS in KRAS
Liu Y; Gao GF; Minna JD; Williams NS; Westover KD
Lung Cancer; 2021 Mar; 153():73-80. PubMed ID: 33465697
[TBL] [Abstract][Full Text] [Related]
59. Next generation sequencing in lung cancer: An initial experience from India.
Gupta P; Saha K; Vinarkar S; Banerjee S; Choudhury SS; Parihar M; Midha D; Mukherjee G; Lingegowda D; Chatterjee S; ArunsinghS M; Shrimali R; Ganguly S; Dabkara D; Biswas B; Mishra DK; Arora N
Curr Probl Cancer; 2020 Jun; 44(3):100562. PubMed ID: 32178863
[TBL] [Abstract][Full Text] [Related]
60. KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-analysis.
Goulding RE; Chenoweth M; Carter GC; Boye ME; Sheffield KM; John WJ; Leusch MS; Muehlenbein CE; Li L; Jen MH; Rojubally A; Jansen J; Druyts E
Cancer Treat Res Commun; 2020; 24():100200. PubMed ID: 32750661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]